濮阳惠成：拟将顺酐酸酐衍生物业务划转至全资子公司

Core Viewpoint - Puyang Huicheng (300481) announced the transfer of assets, liabilities, business, personnel, and qualifications related to its anhydride derivative business to its wholly-owned subsidiary, Henan Huicheng, as part of an internal resource integration strategy aimed at optimizing asset structure and improving operational efficiency [1] Group 1: Asset Transfer Details - The transfer is set to take place on November 30, 2025, with total assets of approximately 267 million yuan (unaudited) and total liabilities of about 14.8024 million yuan [1] - The asset transfer will occur without any cash consideration from Henan Huicheng [1] Group 2: Strategic Implications - The company stated that this asset transfer aligns with its overall development strategy and will enhance its comprehensive competitiveness [1] - The transfer will not change the scope of the company's consolidated financial statements and is not expected to have a significant impact on future financial conditions or operating results [1]